AdvisorShares Psychedelics ETF (PSIL)
- Previous Close
1.0900 - Open
1.0600 - Bid --
- Ask --
- Day's Range
1.0400 - 1.0800 - 52 Week Range
1.0400 - 2.2490 - Volume
116,507 - Avg. Volume
68,012 - Net Assets 6.54M
- NAV 1.05
- PE Ratio (TTM) --
- Yield 0.29%
- YTD Daily Total Return -21.58%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.99%
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
AdvisorShares
Fund Family
Miscellaneous Sector
Fund Category
6.54M
Net Assets
2021-09-15
Inception Date
Performance Overview: PSIL
Trailing returns as of 6/7/2024. Category is Miscellaneous Sector.
People Also Watch
Holdings: PSIL
Top 10 Holdings (68.94% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: PSIL
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetJohnson & Johnson Earnings: Growth Outlook Slowing After Solid 2023, but Pipeline Holds Upside
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetJohnson & Johnson: Split Off of Consumer Unit Kenvue Likely Final Step in Unit’s Divestment
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetLowering target price to $29.00
FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $29.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target